SARS-COV-2 Proteins, in Complex with Tirilazad

I.V. Ferrari¹ , M. Di Mario²

Section:Research Paper, Product Type: Journal-Paper
Vol.10 , Issue.1 , pp.19-25, Feb-2022

Online published on Feb 28, 2022

Copyright © I.V. Ferrari, M. Di Mario . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

Abstract :
In this study, our approach was to carry out a complete investigation of molecular docking analysis with the major SARS-CoV-2 proteins. We analysed more than 6000 drugs, downloaded by the PubChem database. Particular attention, we have focused on Spike Glycoprotein and Main protease 3CLpro Covid-19 proteins, by “Blind docking” method and “Selective docking” procedure, in Ligand Binding site, with AutoDock Vina using Pyrx software. From our results, we have selected Tirilazad against COVID-19. In fact, it reported having an excellent ability to bind both with the “Native Spike Glycoprotein”, with a Binding Energy of -11.8 kcal mol-1, and with the South African (B.1.351) SARS-CoV-2 spike protein variant, with a Binding Energy -10 kcal mol-1. Indeed, in the second case, the docking analysis was evaluated in the active area of three key amino acids belonging to the Spike Protein RBD, responsible for a higher binding with the ACE2 receptor. They are ASN 417, Lys 484, and Tyr 501 respectively. In addition, Tirilazad has shown a Binding energy score of approximately -10.5 kcal mol-1 against SARS-COV-2 Main protease. This has led us to conclude that this drug could be an excellent candidate against Coronavirus (COVID-19) pandemic, even though further in vitro and in vivo studies are needed.

Key-Words / Index Term :
Tirilazad; SARS-COV-2

References :
[1] Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G. F.; Tan, and W. “A Novel Coronavirus from Patients with Pneumonia in China, 2019”, New England Journal of Medicine , Vol.382, Issue.8, pp.727–733, 2020, https://doi.org/10.1056/nejmoa2001017.
[2] Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; and Zhang, L. “Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study”, The Lancet , Vol.395 , Issue. 10223, pp.507–513, 2020, https://doi.org/10.1016/S0140-6736(20)30211-7.
[3] Nobel, Y. R.; Phipps, M.; Zucker, J.; Lebwohl, B.; Wang, T. C.; Sobieszczyk, M. E.; and Freedberg, D. E. “Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States”, Gastroenterology , Vol.159, Issue.1, pp.373-375, 2020, https://doi.org/10.1053/j.gastro.2020.04.017.
[4] Gautier, J. F.; and Ravussin, Y. “A New Symptom of COVID-19: Loss of Taste and Smell. Obesity”, Blackwell Publishing Inc. Vol.28, Issue.5, pp.848, 2020, https://doi.org/10.1002/oby.22809.
[5] Cao, X. “COVID-19: Immunopathology and Its Implications for Therapy”, Nature Reviews Immunology, Vol. 20, Issue.5, pp. 269–270, 2020, https://doi.org/10.1038/s41577-020-0308-3.
[6] Basile, C.; Combe, C.; Pizzarelli, F.; Covic, A.; Davenport, A.; Kanbay, M.; Kirmizis, Di.; Schneditz, D.; van der Sande, F.; and Mitra, S. “Recommendations for the Prevention, Mitigation and Containment of the Emerging SARS-CoV-2 (COVID-19) Pandemic in Haemodialysis Centres” Nephrology Dialysis Transplantation , Vol.35, Issue.5, pp.737–741. https://doi.org/10.1093/ndt/gfaa069.
[7] Sabetkish, N.; and Rahmani, A.” The Overall Impact of COVID ?19 on Healthcare during the Pandemic: A Multidisciplinary Point of View “Health Science Reports, Vol.4, Issue.4, pp.e386,2021, https://doi.org/10.1002/hsr2.386.
[8] González, J. M.; Gomez-Puertas, P.; Cavanagh, D.; Gorbalenya, A. E.; and Enjuanes, L. “A Comparative Sequence Analysis to Revise the Current Taxonomy of the Family Coronaviridae,” Archives of Virology, Vol.148, Issue.11, pp.2207–2235, 2003, https://doi.org/10.1007/s00705-003-0162-1.
[9] Zhu, M. “SARS Immunity and Vaccination, Cell Mol Immunol, Vol. 1, Issue. 3, pp.193-8, 2004.
[10] Kandeel, M.; Ibrahim, A.; Fayez, M.; and Al-Nazawi, M. “From SARS and MERS CoVs to SARS-CoV-2: Moving toward More Biased Codon Usage in Viral Structural and Nonstructural Genes,” Journal of Medical Virology , Vol.92, Issue 6, pp. 660–666, 2020, https://doi.org/10.1002/jmv.25754.
[11] Azhar, E. I.; El-Kafrawy, S. A.; Farraj, S. A.; Hassan, A. M.; Al-Saeed, M. S.; Hashem, A. M.; and Madani, T. A. “Evidence for Camel-to-Human Transmission of MERS Coronavirus”, New England Journal of Medicine, Vol.370, Issue 26, pp.2499–2505,2014, https://doi.org/10.1056/nejmoa1401505.
[12] Ita, K. “Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development,” Archives of Medical Research. Elsevier Inc, Vol.52, Issue. 1, pp.15–24, 2021,https://doi.org/10.1016/j.arcmed.2020.09.010.
[13] Gil, C.; Ginex, T.; Maestro, I.; Nozal, V.; Barrado-Gil, L.; Cuesta-Geijo, M. Á.; Urquiza, J.; Ramírez, D.; Alonso, C.; Campillo, N. E.; Martinez, A. COVID-19: Drug Targets and Potential Treatments. Journal of Medicinal Chemistry,” American Chemical Society, Vol.63, Issue 21, pp.12359–12386, 2020, https://doi.org/10.1021/acs.jmedchem.0c00606.
[14] Tahir ul Qamar, M.; Alqahtani, S. M.; Alamri, M. A.; and Chen, L. L. “Structural Basis of SARS-CoV-2 3CLpro and Anti-COVID-19 Drug Discovery from Medicinal Plants, Journal of Pharmaceutical Analysis , Vol. 10, Issue. 4, pp. 313–319, 2020, https://doi.org/10.1016/j.jpha.2020.03.009.
[15] Mody, V.; Ho, J.; Wills, S.; Mawri, A.; Lawson, L.; Ebert, M. C. C. J. C.; Fortin, G. M.; Rayalam, and S.; Taval, S.” Identification of 3-Chymotrypsin like Protease (3CLPro) Inhibitors as Potential Anti-SARS-CoV-2 Agents, Communications Biology , Vol.4, Issue.1,pp.1-10, 2021, https://doi.org/10.1038/s42003-020-01577-x.
[16] Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C.; Hohmann, E.; Chu, H. Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R. W.; Dierberg, K.; Tapson, V.; Hsieh, L.; Patterson, T. F.; Paredes, R.; Sweeney, D. A.; Short, W. R.; Touloumi, G.; Lye, D. C.; Ohmagari, N.; Oh, M.; Ruiz-Palacios, G. M.; Benfield, T.; FĂ€tkenheuer, G.; Kortepeter, M. G.; Atmar, R. L.; Creech, C. B.; Lundgren, J.; Babiker, A. G.; Pett, S.; Neaton, J. D.; Burgess, T. H.; Bonnett, T.; Green, M.; Makowski, M.; Osinusi, A.; Nayak, S.; and Lane, H. C. “Remdesivir for the Treatment of Covid-19”, New England Journal of Medicine ,Vol.383, Issue.19, pp. 1813–1826, 2020, https://doi.org/10.1056/nejmoa2007764.
[17] Boulware, D. R.; Pullen, M. F.; Bangdiwala, A. S.; Pastick, K. A.; Lofgren, S. M.; Okafor, E. C.; Skipper, C. P.; Nascene, A. A.; Nicol, M. R.; Abassi, M.; Engen, N. W.; Cheng, M. P.; LaBar, D.; Lother, S. A.; MacKenzie, L. J.; Drobot, G.; Marten, N.; Zarychanski, R.; Kelly, L. E.; Schwartz, I. S.; McDonald, E. G.; Rajasingham, R.; Lee, T. C.; and Hullsiek, K. H. “A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19,” New England Journal of Medicine , Vol.383, Issue.6, pp. 517–525, 2020, https://doi.org/10.1056/nejmoa2016638.
[18] Maskin, L. P.; Olarte, G. L.; Palizas, F.; Velo, A. E.; Lurbet, M. F.; Bonelli, I.; Baredes, N. D.; and Rodríguez, P. O. “High Dose Dexamethasone Treatment for Acute Respiratory Distress Syndrome Secondary to COVID-19: A Structured Summary of a Study Protocol for a Randomised Controlled Trial, Trials , Vol.21, Issue.1, pp.1-3,2020https://doi.org/10.1186/s13063-020-04646-y.
[19] Morales-Ortega, A.; Bernal-Bello, D.; Llarena-Barroso, C.; Frutos-Pérez, B.; Duarte-Millån, M. Á.; García de Viedma-García, V.; and Farfån-Sedano, A. I.; Canalejo-Castrillero, E.; Ruiz-Giardín, J. M.; Ruiz-Ruiz, J.; San Martín-López, J. V. Imatinib for COVID-19: A Case Report. Clinical immunology (Orlando, Fla.) , Vol. 218, pp.108518,2020, https://doi.org/10.1016/j.clim.2020.108518.
[20] Musarrat, F.; Chouljenko, V.; Dahal, A.; Nabi, R.; Chouljenko, T.; Jois, S. D.; and Kousoulas, K. G. “The Anti-HIV Drug Nelfinavir Mesylate (Viracept) Is a Potent Inhibitor of Cell Fusion Caused by the SARSCoV-2 Spike (S) Glycoprotein Warranting Further Evaluation as an Antiviral against COVID-19 Infections,” Journal of Medical Virology, Vol.92, Issue.10, pp. 2087–2095, 2020, https://doi.org/10.1002/jmv.25985.
[21] Thachil, J. “The Versatile Heparin in COVID-19”, Journal of Thrombosis and Haemostasis. Blackwell Publishing Ltd, pp 1020–1022, 2020, https://doi.org/10.1111/jth.14821.
[22] Boretti, A.” Favipiravir Use for SARS CoV-2 Infection,” Pharmacological Reports , Vol.72, Issue.6, pp. 1542–1552, 2020, https://doi.org/10.1007/s43440-020-00175-2 .
[23] Zhu, Z.; Lu, Z.; Xu, T.; Chen, C.; Yang, G.; Zha, T.; Lu, J.; and Xue, Y. “Arbidol Monotherapy Is Superior to Lopinavir/Ritonavir in Treating COVID-19,” Journal of Infection , Vol. 81, Issue.1 , pp. e21–e23,2020, https://doi.org/10.1016/j.jinf.2020.03.060.
[24] Hippensteel, J. A.; Lariviere, W. B.; Colbert, J. F.; LangouĂ«t-AstriĂ©, C. J.; and Schmidt, E. P. “Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities,” Am J Physiol Lung Cell Mol Physiol , Vol.319, pp. 211–217, 2020, https://doi.org/10.1152/ajplung.00199.2020.-Coronavirus.
[25] Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; and Wang, C. “A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,” New England Journal of Medicine , Vol. 382, Issue.19, pp.1787–1799, 2020, https://doi.org/10.1056/nejmoa2001282.
[26] Wegner, J. K., Sterling, A., Guha, R., Bender, A., Faulon, J. L., Hastings, J. and Willighagen, E. “Cheminformatics”, Communications of the ACM, Vol. 55, Issue.11, pp.65-75, 2012.
[27] Trott, O., and Olson, A. J. “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading”, Journal of computational chemistry, Vol.31, Issue.2, pp.455-461, 2010.
[28] Dallakyan, S., and Olson, A. J. “Small-molecule library screening by docking with PyRx,”In Chemical biology pp. 243-250, Humana Press, New York, NY, 2015.
[29] ValdĂ©s-Tresanco, M. S., ValdĂ©s-Tresanco, M. E., Valiente, P. A., and Moreno, E. “AMDock: a versatile graphical tool for assisting molecular docking with Autodock Vina and Autodock4,” Biology direct, Vol. 15, Issue.1, pp. 1-12,2020.
[30] Jejurikar, B. L., and Rohane, S. H.” Drug Designing in Discovery Studio”, Asian Journal of Research in Chemistry, Vol. 14, Issue.2, pp.135-138, 2021.
[31] Wallace, A. C., Laskowski, R. A., AND Thornton, J. M.” LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions,” Protein engineering, design and selection, Vol. 8, Issue.2 , pp. 127-134, 1995.
[32] Bracken, M. B., Shepard, M. J., Holford, T. R., Leo-Summers, L., Aldrich, E. F., Fazl, M., and Young, W. “Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up: results of the third National Acute Spinal Cord Injury randomized controlled trial”, Journal of neurosurgery, Vol.89, Issue.5, pp.699-706,1998.
[33] Schmid-Elsaesser, R., Zausinger, S., Hungerhuber, E., Baethmann, A., and Reulen, H. J. “ Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischemia. Neurosurgery, Vol. 44, Issue.1, pp.163-171,1998.